Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9H3H3

UPID:
CK068_HUMAN

ALTERNATIVE NAMES:
Basophilic leukemia-expressed protein Bles03; Protein p5326

ALTERNATIVE UPACC:
Q9H3H3; J3KQG9; Q9BT13

BACKGROUND:
UPF0696 protein C11orf68, known alternatively as Basophilic leukemia-expressed protein Bles03 and Protein p5326, is a protein of interest in the field of molecular biology. Despite its discovery, the comprehensive understanding of its functions and the pathways it influences remains incomplete. This gap in knowledge presents an opportunity for in-depth study to uncover the protein's full spectrum of activities.

THERAPEUTIC SIGNIFICANCE:
The exploration of UPF0696 protein C11orf68's function is not just an academic pursuit but a journey towards uncovering novel therapeutic avenues. Although its direct link to specific diseases has not been identified, the protein's involvement in fundamental cellular processes hints at its potential as a key player in disease mechanisms. This makes it a compelling target for the development of innovative treatment strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.